Dr. MartinWeber

Partner

(T) 49.89.20.60.42.200

As a patent lawyer with 25 years of experience, Dr. Martin Weber represents clients in the life sciences, biotechnology, pharmaceuticals, and chemistry sectors, focusing on patent prosecution, opposition and appeal proceedings, patent invalidation, and patent infringement. In addition, he advises on patent portfolio strategies in relation to regulatory and patent exclusivity involving patent term extensions (supplementary protection certificates) for medicinal and plant protection products within the European Communities.

Drawing on his training in chemistry and biochemistry, Martin has counseled clients in technologies involving inorganic, organic, and polymer chemistry; pharmaceuticals; biotechnology (such as functional genomics, proteomics, tissue engineering, and genetic engineering); biologics (antibodies, growth factors, and peptide drugs); therapies (such as antiviral and anti-angiogenic therapies, nanomedicine, gene therapy, and personalized medicine); and diagnostics.

Martin leads Jones Day's German and European patent prosecution team and is a former scholar of the German National Academic Foundation.

Experience

  • Total sells Atotech to The Carlyle Group for $3.2 billionJones Day advised Total in the $3.2 billion sale of specialty chemical affiliate Atotech B.V., a global manufacturer of high technology plating solutions, to The Carlyle Group.
  • Akebia successfully challenges European patentJones Day represented Akebia Therapeutics, Inc. in successfully challenging the validity of European Patent No. EP1463823 issued to FibroGen, Inc. in opposition proceedings before the European Patent Office ("EPO").
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Puma Biotechnology defends European patent licensed from Wyeth covering Neratinib and Vinorelbine in opposition proceedingsJones Day represents Puma Biotechnology, Inc. in European opposition proceedings initiated by Mylan to defend a patent licensed from Wyeth covering Neratinib and Vinorelbine.
  • Celgene defends its patent covering pomalidomide and dexamethasone in EP opposition proceedingsJones Day represents Celgene Corporation in opposition proceedings initiated by six generic companies regarding a Celgene European patent covering pomalidomide and dexamethasone.
  • Idenix asserts patent infringement against Gilead in France related to Sovaldi® and Harvoni®Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Tribunal de Grande Instance de Paris in France over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • Idenix enforces patent against Gilead in Germany over sofosbuvirJones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Landgericht Düsseldorf in Germany over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • Celgene appeals decision from Opposition Division to revoke lenalidimide European patentJones Day represents Celgene Corporation in the appeal of a decision in opposition proceedings against two generic companies opposing a Celgene European patent covering the polymorphs of lenalidimide.
  • Celgene establishes global patent portfolio for its brands REVLIMID®, POMALYST®, OTEZLA®, VIDAZA®, ABRAXANE® and ISTODAX®Jones Day assists Celgene Corporation in the establishment of its global patent portfolio related to lenalidomide (REVLIMID®), pomalidomide POMALYST®), apremilast (OTEZLA®), azacitidine (VIDAZA®), ABRAXANE® and romidepsin (ISTODAX®) for the treatments of cancer and immune, inflammatory conditions.
  • Leading U.S. cancer research institute successfully defends antibody patent in EuropeJones Day successfully represented major U.S. cancer research institute in opposition proceedings before the European Patent Office.
  • Leading manufacturer of low ignition proclivity papers engages in European oppositionsJones Day represents a leading paper manufacturer before the European Patent Office. 
  • Abraxis BioScience successfully defends patent covering platform technology for nanoparticles of protein coated drugs in Opposition ProceedingJones Day successfully defended Abraxis Bioscience's patent covering its platform technology - Nab™ - for protein coated nanoparticles opposed by Teva Pharmaceutical Industries in January 2010.
  • Leading immunodiagnostics manufacturer successfully challenges competitor's patentJones Day successfully represented a leading global immunodiagnostics manufacturer in EPO opposition proceedings against one of its main competitors.
  • Genomatica establishes global patent portfolios related to production of more sustainable versions of major chemicals, made from alternative feedstocksJones Day represents Genomatica in the development of a worldwide patent portfolio related to methods of producing high-volume basic and intermediate chemicals from alternative feedstocks, such as sugars and cellulosic biomass, using engineered microorganisms.
  • Celgene defends patents covering lenalidomide and apremilast before European Patent OfficeJones Day represents Celgene Corporation in defense of patents covering lenalidomide and apremilast against oppositions brought before the European Patent Office by generic pharmaceutical companies.
  • Mount Sinai School of Medicine enforces patent on key biotech pharmaceutical productJones Day represented Mount Sinai School of Medicine of New York University in a multinational cross-jurisdictional patent infringement litigation against a global pharmaceutical company.
  • Global diagnostics manufacturer challenges patent for test kit for detecting paraneoplastic neurological syndromesJones Day represents an international manufacturer of medical laboratory diagnostics in a nullity action against a patent relating to a test kit for detecting paraneoplastic neurological syndromes.
  • Global diagnostics manufacturer defends against patent infringement charges over test kit for detecting paraneoplastic syndromeJones Day represents an international manufacturer of medical laboratory diagnostics in a patent litigation relating to a test kit for detecting paraneoplastic syndrome.
  • Global diagnostics manufacturer challenges patent for a test kit for detecting tissue transglutaminaseJones Day is representing an international manufacturer of medical laboratory diagnostics in a nullity action against the German part of a European patent relating to a test kit for tissue transglutaminase.
  • Global diagnostics manufacturer defends market position in patent infringement dispute over test kit for tissue transglutaminaseJones Day represents an international manufacturer of medical laboratory diagnostics in a multi-jurisdiction patent infringement dispute over a test kit for tissue transglutaminase.
  • Additional Publications

    • 2008Das neue Gendiagnostikgesetz, GoingPublic "Biotechnologie 2008"
    • April 2003The Utility Model Revisited, Managing Intellectual Property
    • September 2001Provisional Protection for Methods of Treatment, Managing Intellectual Property
    • November 2000Chemical Compounds and equivalents, Managing Intellectual Property
    • October 2000Supplementary Protection Certificates (2), Managing Intellectual Property
    • June 1999Supplementary Protection Certificates, Managing Intellectual Property

    Speaking Engagements

    • June 16-17, 2009
      Biotech Patenting - Drafting Successful Patent Applications for Biotechnology Related Inventions, 16th Forum (European Edition) Biotech Patenting Conference
    • March 4-5, 2009
      Inventions and Patents, Science4Life Workshop, in connection with the Science4Life Venture Cup 2009
    • September 23-24, 2008
      Intellectual Property Aspects in Formulating Co-Crystals, Pharmaceutical Co-Crystals 2008 Conference (Pharma IQ/IQPC)
    • March 12-13, 2008
      Inventions and Patents, Science4Life Workshop, in connection with the Science4Life Venture Cup 2008
    • September 11, 2007
      Patent law and strategic aspects in connection with developing pharmaceutical products and diagnostics, Seminar at the Chambers of Industry and Commerce
    • July 11, 2006
      LifeSciences and Biotech Patents - Impact of the EU Biotechnology Guideline on the Protection of Innovations, Seminar at the Technology Center
    • September 2, 2005
      LifeSciences and Biotech Patents - Impact of the EU Biotechnology Guideline on the Protection of Innovations, Seminar of the Innovation and Patent Center (IPC)
    • February 8-10, 2004
      Canada, Europe, and the United States - Why you may need to understand different IP regimes to obtain an appropriate deal structure, 2nd Annual BioPartnering North America (BPN) conference
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.